Cat. No. 1227
Chemical Name: 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
Biological ActivityProtein kinase inhibitor. Suppresses tumor-promoting effects of TPA and exhibits antiproliferative activity in human breast cancer cells (IC50 values are 59.44 and 31.15 μM at 24 and 72 hrs respectively). Activates both the intrinsic and extrinsic apoptotic pathways and displays anti-inflammatory, hypotensive, antispasmodic and antioxidant properties in vivo.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Sato et al (1994) Apigenin induces morphological differentiation and G2-M arrest in rat neuronal cells. Biochem.Biophys.Res.Commun. 204 578. PMID: 7980517.
Kuo and Yang (1995) Reversion of v-H-ras-transformed NIH3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem.Biophys.Res.Commun. 212 767. PMID: 7626110.
Lin et al (1997) Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J.Cell.Biochem.Suppl. 28-29 39. PMID: 9589348.
Choi et al (2009) Apigen induces apoptosis through a mitochondria/caspase-pathway in human breast cancer MDA-MB-453 cells. J.Clin.Biochem.Nutr. 44 260. PMID: 19430615.
Jin et al (2009) Apigenin protects endothelium-dependent relaxation of rat aorta against oxidative stress. Eur.J.Pharmacol. 616 200. PMID: 19549516.
If you know of a relevant citation for this product please let us know.
Keywords: Apigenin, supplier, Protein, kinase, inhibitors, Kinases, Broad, Spectrum
Find multiple products by catalog number
New Products in this Area
Potent protein kinase D (PKD) inhibitorHarmine
Potent and selective Dyrk1A inhibitorAZ 628
Potent Raf kinase inhibitorCHIR 99021 trihydrochloride
Hydrochloride salt of CHIR 99021 (Cat. No. 4423); selective GSK-3 inhibitorYZ9
PFKFB3 inhibitor; inhibits cell growthKU 0060648
Dual DNA-PK and PI 3-K inhibitorKB SRC 4
Potent and selective c-Src inhibitorProINDY
Dyrk1A/B inhibitor; prodrug of INDY (Cat. No. 4997)INDY
Dyrk1A/B inhibitorAZD 6482
Potent and selective PI 3-Kβ inhibitorAS 1892802
Potent ROCK inhibitor; orally bioavailableSC 79
Akt activatorSNS 314 mesylate
Potent pan-Aurora kinase inhibitorPD 180970
p210bcr/abl kinase inhibitor; also inhibits c-Src and KITPD 334581
MEK1 inhibitorSB 747651A dihydrochloride
Potent MSK1 inhibitor; also inhibits other AGC group kinases
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.